Study of rezpegaldesleukin for moderate to severe eczema
Part of Immune system & allergy, Skin clinical trials.
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old and weigh at least 40 kg (about 88 pounds).
- You have had eczema for at least 12 months and it is moderate to severe (covering at least 10% of your body).
- Your eczema score (EASI) is 16 or higher, which means it's significant.
- You have tried prescription creams but they didn't help enough, or you couldn't use them.
- You cannot have started certain treatments before this study, like other injected biologic drugs or JAK inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
This trial tests an injectable drug called lebrikizumab for people with moderate-to-severe eczema (atopic dermatitis) that has not been well controlled with topical treatments. It may help reduce skin symptoms and itching.
This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.